

IMMUNOBIOLOGICS

IMMUNOBIOLOGIC	PRIMARY IMMUNIZATION SCHEDULE	BOOSTER SCHEDULE	COMMENTS AND CONTRAINDICATIONS
<p>Yellow Fever Vaccine (Live, Attenuated)</p> <p>YF-VAX® Sanofi Pasteur</p>	<p>Children 9 months of age or over and adults</p> <p>Dose: 0.5 mL SC*</p> <p>* Subcutaneous</p>	<p>Dose: 0.5 mL SC every 10 years</p>	<p>Yellow fever (YF) vaccines must be administered at an approved yellow fever vaccination center. Give vaccine recipients a completed International Certificate of Vaccination or Prophylaxis (ICVP), signed and validated with the center's stamp where the vaccine was given. This certificate is valid 10 days after vaccination and for a subsequent period of 10 years.</p> <p>YF vaccine is indicated for persons living or traveling in endemic areas of South America and Africa, or traveling to countries that require a certificate of vaccination against yellow fever. YF vaccine requirements by country and CDC's recommendations for vaccination can be found at http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/yellow-fever-vaccine-requirements-and-recommendations.aspx. Laboratory personnel with occupational risk exposure should be immunized.</p> <p>Due to the risk of serious adverse events that can occur following YF vaccination, only vaccinate persons who: 1) are at risk of exposure to YF virus, or 2) require proof of vaccination for country entry. Carefully observe the contraindications and consider the precautions to vaccination prior to administration of YF vaccine.</p> <p>Infants between 6 and 9 months can be considered for vaccination when risk of infection is high. Infants younger than 6 months should not be immunized because they have an increased susceptibility for vaccine-associated neurotropic disease. If considering vaccinating infants less than 9 months or pregnant women call CDC at 800-CDC-INFO (800-232-4636) for further advice.</p> <p>Adverse Reactions:</p> <ul style="list-style-type: none"> • Low-grade fever, headache, and myalgias are common. • Localized pain, swelling, erythema, or warmth might occur at the injection site for up to a week following vaccination. • Anaphylaxis occurs at a rate of 0.8 to 1.8 cases per 100,000 doses administered. • <i>Yellow Fever Vaccine-Associated Neurologic Disease (YEL-AND)</i> represents a conglomerate of different clinical syndromes, including meningoencephalitis, Guillain-Barré syndrome (GBS), acute disseminated encephalomyelitis (ADEM), bulbar palsy, and Bell's palsy. Historically, YEL-AND was seen primarily among infants as encephalitis, but more recent reports have been among persons of all ages. The incidence of YEL-AND in the United States is 0.8 per 100,000 doses administered. The rate is higher in persons ≥60 years of age, with a rate of 1.6 per 100,000 doses in persons 60–69 years of age and 2.3 per 100,000 doses in persons ≥70 years of age. • <i>Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD)</i> is a severe illness similar to wild-type disease, with vaccine virus proliferating in multiple organs and often leading to multisystem organ failure and death. The incidence of YEL-AVD in the United States is 0.4 cases per 100,000 doses of vaccine administered. The rate is higher for persons ≥60 years of age, with a rate of 1 per 100,000 doses in persons 60–69 years of age and 2.3 per 100,000 doses in persons aged ≥70 years of age. <p>Precautions:</p> <ul style="list-style-type: none"> • Age 6 to 8 months and Age 60 years and older

IMMUNOBIOLOGICS

<p>Yellow Fever Vaccine (Live, Attenuated) _cont.</p>			<ul style="list-style-type: none"> • HIV infection with moderate immune suppression (i.e., CD4 counts of 200–499 per mm³ for persons aged 6 years and over or 15%–24% of total lymphocytes for children aged under 6 years) • Pregnancy and Breastfeeding <p>Contraindications:</p> <ul style="list-style-type: none"> • Anaphylactic hypersensitivity to a prior dose or to a vaccine component, including egg, chicken protein, or gelatin. Anaphylaxis has been reported to occur in persons with no history of reactions to the components of the vaccine. Observe all patients for at least 15 minutes following the administration of the vaccine, and epinephrine injection (1:1,000) should be readily available in case of a serious allergic reaction. Furthermore, because reactions have been delayed up to several hours following YF vaccine, all patients should be advised of signs and symptoms of an allergic reaction (e.g., urticaria, angioedema, rash, dyspnea, bronchospasm, pharyngeal edema, wheezing, and throat tightness). In addition, vaccinated persons should be advised to seek immediate medical care if any symptoms of an allergic reaction develop following vaccination. • Age less than 6 months • Primary immunodeficiencies; Malignant neoplasms; Transplantation; Immunosuppressive and immunomodulatory therapies • Symptomatic HIV infection or CD4+ T-lymphocytes less than 200/mm³ (or less than 15% of total lymphocytes in children under 6 years of age) • Thymus disease, including myasthenia gravis, thymoma, or prior thymectomy
---	--	--	---